David Dai
Stock Analyst at Bernstein
(2.02)
# 3,066
Out of 5,132 analysts
32
Total ratings
41.38%
Success rate
-3.75%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASML ASML Holding | Maintains: Outperform | $1,528 → $1,642 | $1,435.63 | +14.37% | 2 | Jan 22, 2026 | |
| SONY Sony Group | Maintains: Outperform | $33 → $30 | $22.95 | +30.72% | 1 | Jan 14, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $4.88 | +43.44% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $7.84 | +104.08% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $109.38 | +6.97% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $21.71 | +75.03% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $103.15 | +27.97% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $6.93 | +188.60% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $16.11 | +61.39% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $15.25 | +96.72% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $2 | $2.60 | -23.08% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $11.96 | +100.67% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $32.97 | -27.20% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.12 | +425.91% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $31.90 | +56.74% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $53.55 | +12.04% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $6.81 | +6,478.56% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $82.09 | -51.27% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.72 | +2,225.58% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.00 | +2,400.00% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $28.27 | +83.94% | 1 | Mar 17, 2020 |
ASML Holding
Jan 22, 2026
Maintains: Outperform
Price Target: $1,528 → $1,642
Current: $1,435.63
Upside: +14.37%
Sony Group
Jan 14, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $22.95
Upside: +30.72%
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $4.88
Upside: +43.44%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $7.84
Upside: +104.08%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $109.38
Upside: +6.97%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $21.71
Upside: +75.03%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $103.15
Upside: +27.97%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $6.93
Upside: +188.60%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $16.11
Upside: +61.39%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $15.25
Upside: +96.72%
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.60
Upside: -23.08%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $11.96
Upside: +100.67%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.97
Upside: -27.20%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.12
Upside: +425.91%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $31.90
Upside: +56.74%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $53.55
Upside: +12.04%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $6.81
Upside: +6,478.56%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $82.09
Upside: -51.27%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.72
Upside: +2,225.58%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.00
Upside: +2,400.00%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $28.27
Upside: +83.94%